|
08.01.2025 13:48:15
|
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
(RTTNews) - Novo Nordisk A/S (NVO), Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease, committing to a near-term payment of $190 million. The collaboration expects milestone payments of approximately $4.6 billion plus R&D funding and potential royalty payments.
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, conducting trials, and developing therapeutics with human-centric AI small molecule design.
In addition to an upfront payment, equity investment, and a potential near-term milestone payment, Valo will also receive milestone payments for up to 20 drug programs, an addition of 9 new drug programs.
In the pre-market hours, Novo Nordisk's stock is climbing 2.84 percent, to $85.72 on the New York Stock Exchange.
Nachrichten zu Novo Nordisk (spons. ADRs)
Analysen zu Novo Nordisk (spons. ADRs)
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Meta Platforms
NEU✅ Microsoft
inklusive Rebalancing:
❌ Arthur J. Gallagher & Co
❌ Progressive
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Novo Nordisk (spons. ADRs) | 82.50 | -0.18% |
|
Siemens Energy am 30.01.2025
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI schwächelt -- DAX mit Verlusten -- Börsen in Fernost uneinig - Nikkei stabilSowohl der heimische als auch der deutsche Aktienmarkt verbuchen zur Wochenmitte Abschläge. Auch die asiatischen Indizes geben indes überwiegend nach, lediglich der Nikkei hält sich knapp im Plus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |